Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous (SQ) dosing i
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies
06:00pm, Thursday, 15'th Jan 2026
VANCOUVER, BC / ACCESS Newswire / January 15, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTC PINK:BBCMF)(Frankfurt:N790, WKN:A41QA9) ("LIR" or the "Company")is pleased to announce the launch of a contr
Healthy Returns: Novo Nordisk CEO on GLP-1 pricing, and more insights from the JPM conference
12:08pm, Wednesday, 14'th Jan 2026
Novo Nordisk CEO Mike Doustdar said 2026 will be the year of "price pressure" as more GLP-1 supply enters the market and pricing deals take effect. Bristol Myers Squibb CEO Chris Boerner said the comp
Is It Time to Dump Your Shares of Eli Lilly?
08:32am, Wednesday, 14'th Jan 2026
Eli Lilly leads in the GLP-1 drug space with its shot-based offerings Mounjaro and Zepbound. Rival drugmaker Novo Nordisk has now introduced a pill version of its GLP-1 weight loss drug.
Global Partners: Upgrading To Strong Buy As Market Fear Creates Value
06:00am, Tuesday, 13'th Jan 2026
Global Partners LP is upgraded to Strong Buy, driven by a resilient business model, 16th consecutive distribution increase, and clear undervaluation. GLP maintains a robust ~7.08% yield with a managea
Global Partners LP Insider Purchases Nearly 4000 Shares To Close Out 2025
03:16am, Tuesday, 13'th Jan 2026
An insider of Global Partners LP acquired 3,917 shares of the company for a transaction value of $176,566.28 in December 2025. The transaction involved only direct ownership; no derivative, gifting, o
Novo Nordisk CEO: People have been waiting for a GLP-1 pill
07:41pm, Monday, 12'th Jan 2026
Mike Doustdar, Novo Nordisk president and CEO, joins 'Mad Money' host Jim Cramer to talk the success of GLP-1, pricing for weight-loss pills and more.
Novo Nordisk sees oral pills capturing over third of GLP-1 market by 2030
03:52pm, Monday, 12'th Jan 2026
Oral weight-loss drugs could make up a third or more of the overall GLP-1 market by 2030, a larger percentage than the company originally anticipated, a Novo Nordisk executive said on Monday.
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
12:36pm, Monday, 12'th Jan 2026
Novo Nordisk CEO Mike Doustdar said on Monday as many as 1.5 million patients in the U.S. may be using compounded versions of blockbuster GLP-1 drugs, underscoring how cheaper, unapproved alternatives
Global Partners Announces Cash Distribution on Series B Preferred Units
08:30am, Monday, 12'th Jan 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (the “Partnership”) today announced that the Board of Directors (the “Board”) of its general partner, Global GP LLC, has declare
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
08:00am, Monday, 12'th Jan 2026
Advancing icovamenib toward late-stage clinical development in two Phase II clinical trials in patients with insulin-deficient type 2 diabetes (“T2D”) and in T2D patients currently failing glucago
Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program
The GLP-1 Blockbuster Maker Widens Its Lead as the Diversified Healthcare Giant Posts Steady Growth
08:59am, Saturday, 10'th Jan 2026
Eli Lilly (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ) both delivered strong third-quarter results, but their earnings revealed two fundamentally different healthcare businesses.
2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
08:00am, Saturday, 10'th Jan 2026
In 2026, new obesity pills will push the booming GLP-1 market into its next chapter. Pills may serve as a more convenient — and in certain cases cheaper — alternative to today's blockbuster inject
Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham
06:22pm, Friday, 09'th Jan 2026
Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.
